And if they work, these drugs will hit the market in the 2030s. That's how long clinical development takes. It is a painful lesson for the first wave of AI-driven biotech (Benevolent AI, Recursion & Exscientia, Owkin...) investors. DD is a long game.
add a skeleton here at some point
11 months ago